177 related articles for article (PubMed ID: 37587335)
41. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
[TBL] [Abstract][Full Text] [Related]
42. Prognostic Significance of Clinical Factors Including
Kim JY; Park H; Lee DW; Kim MJ; Shin JE; Lee KE; Lee HN
Anticancer Res; 2022 Oct; 42(10):4945-4954. PubMed ID: 36191979
[TBL] [Abstract][Full Text] [Related]
43. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
[TBL] [Abstract][Full Text] [Related]
44. Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers.
Bijron JG; van der Groep P; van Dorst EB; Seeber LM; Sie-Go DM; Verheijen RH; van Diest PJ
Endocr Relat Cancer; 2012 Feb; 19(1):69-81. PubMed ID: 22143498
[TBL] [Abstract][Full Text] [Related]
45. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].
Wen J; Shi JL; Shen DH; Chen YX; Song QJ
Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451
[TBL] [Abstract][Full Text] [Related]
46. The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1--deficient ovarian tumors and can be exploited to improve treatment response in a mouse model.
Mantia-Smaldone G; Ronner L; Blair A; Gamerman V; Morse C; Orsulic S; Rubin S; Gimotty P; Adams S
Gynecol Oncol; 2014 Jun; 133(3):584-90. PubMed ID: 24680909
[TBL] [Abstract][Full Text] [Related]
47. Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.
Baert T; Vankerckhoven A; Riva M; Van Hoylandt A; Thirion G; Holger G; Mathivet T; Vergote I; Coosemans A
Front Immunol; 2019; 10():1273. PubMed ID: 31214202
[TBL] [Abstract][Full Text] [Related]
48. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.
Schrader KA; Hurlburt J; Kalloger SE; Hansford S; Young S; Huntsman DG; Gilks CB; McAlpine JN
Obstet Gynecol; 2012 Aug; 120(2 Pt 1):235-40. PubMed ID: 22776961
[TBL] [Abstract][Full Text] [Related]
49. The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube.
Xian W; Miron A; Roh M; Semmel DR; Yassin Y; Garber J; Oliva E; Goodman A; Mehra K; Berkowitz RS; Crum CP; Quade BJ
J Pathol; 2010 Jan; 220(1):17-23. PubMed ID: 19834951
[TBL] [Abstract][Full Text] [Related]
50. Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.
Rabban JT; Crawford B; Chen LM; Powell CB; Zaloudek CJ
Am J Surg Pathol; 2009 Jan; 33(1):111-9. PubMed ID: 18830124
[TBL] [Abstract][Full Text] [Related]
51. Cytomorphologic and molecular analyses of fallopian tube fimbrial brushings for diagnosis of serous tubal intraepithelial carcinoma.
Chui MH; Vang R; Wang TL; Shih IM; VandenBussche CJ
Cancer Cytopathol; 2019 Mar; 127(3):192-201. PubMed ID: 30861338
[TBL] [Abstract][Full Text] [Related]
52. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
Belanger MH; Dolman L; Arcand SL; Shen Z; Chong G; Mes-Masson AM; Provencher D; Tonin PN
J Ovarian Res; 2015 Mar; 8():1. PubMed ID: 25884701
[TBL] [Abstract][Full Text] [Related]
53. Spontaneous Transformation of a p53 and Rb-Defective Human Fallopian Tube Epithelial Cell Line after Long Passage with Features of High-Grade Serous Carcinoma.
Chang YH; Chu TY; Ding DC
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430324
[TBL] [Abstract][Full Text] [Related]
54. Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.
Reyes MC; Arnold AG; Kauff ND; Levine DA; Soslow RA
Mod Pathol; 2014 Oct; 27(10):1405-11. PubMed ID: 24577588
[TBL] [Abstract][Full Text] [Related]
55. Serous carcinogenesis in the fallopian tube: a descriptive classification.
Jarboe E; Folkins A; Nucci MR; Kindelberger D; Drapkin R; Miron A; Lee Y; Crum CP
Int J Gynecol Pathol; 2008 Jan; 27(1):1-9. PubMed ID: 18156967
[TBL] [Abstract][Full Text] [Related]
56. Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines.
Nash MA; Lenzi R; Edwards CL; Kavanagh JJ; Kudelka AP; Verschraegen CF; Platsoucas CD; Freedman RS
Clin Exp Immunol; 1998 May; 112(2):172-80. PubMed ID: 9649178
[TBL] [Abstract][Full Text] [Related]
57. Progesterone Prevents High-Grade Serous Ovarian Cancer by Inducing Necroptosis of p53-Defective Fallopian Tube Epithelial Cells.
Wu NY; Huang HS; Chao TH; Chou HM; Fang C; Qin CZ; Lin CY; Chu TY; Zhou HH
Cell Rep; 2017 Mar; 18(11):2557-2565. PubMed ID: 28297660
[TBL] [Abstract][Full Text] [Related]
58. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
59. Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Casey MJ; Bewtra C; Lynch HT; Snyder C; Stacy M; Watson P
Fam Cancer; 2013 Dec; 12(4):719-40. PubMed ID: 23666231
[TBL] [Abstract][Full Text] [Related]
60. Immunohistochemical detection of glucose transporter GLUT1 in benign and malignant fallopian tube epithelia, with comparison to ovarian carcinomas.
Kalir T; Rahaman J; Hagopian G; Demopoulos R; Cohen C; Burstein DE
Arch Pathol Lab Med; 2005 May; 129(5):651-4. PubMed ID: 15859637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]